Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Korro Bio aims to develop transformative medicines targeting both rare and highly prevalent indications by activating biological pathways [3] - The company utilizes a chemically modified oligonucleotide or RNA to effect changes in protein structure through RNA editing, specifically changing adenosine to inosine without altering DNA [3] Presentation Context - The presentation was introduced by Henry Jiang from JPMorgan, highlighting the significance of the event and the presence of Korro Bio's leadership [1][2] - Ram Aiyar, the President and CEO of Korro Bio, expressed gratitude for the opportunity to present and emphasized the company's mission [2]